8-K: Travere Therapeutics Reports Strong First Quarter 2025 Results Driven by FILSPARI Growth

Travere Therapeutics announces positive Q1 2025 financial results, highlighted by a 182% year-over-year increase in FILSPARI U.S. net product sales and progress in expanding FILSPARI into FSGS.

Summary

• Travere Therapeutics reported its first quarter 2025 financial results on May 1, 2025.
• Net product sales for Q1 2025 were $75.9 million, compared to $40.0 million for the same period in 2024, driven by FILSPARI sales.
• U.S. net product sales of FILSPARI totaled $55.9 million in Q1 2025.
• The company received 703 new patient start forms (PSFs) for FILSPARI in Q1 2025.
• Research and development (R&D) expenses for Q1 2025 were $46.9 million, compared to $49.4 million in 2024.
• Selling, general, and administrative (SG&A) expenses for Q1 2025 were $72.8 million, compared to $64.2 million in 2024.
• Net loss for Q1 2025 was $41.2 million, or $0.47 per basic share, compared to a net loss of $136.1 million, or $1.76 per basic share in 2024.
• As of March 31, 2025, the company had $322.2 million in cash, cash equivalents, and marketable securities.
• The company submitted an sNDA seeking priority review for traditional approval of FILSPARI in FSGS.
• The company expects a PDUFA target action date of August 28, 2025, for its sNDA requesting modification of liver monitoring and removal of embryo-fetal toxicity monitoring REMS for FILSPARI.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, regulatory progress, and a clear path forward. While there are risks and expenses, the overall tone is optimistic and suggests a promising future for the company.

Positives

• FILSPARI is now fully approved for IgAN in Europe and the UK.
• The company is on track to restart enrollment in the Phase 3 HARMONY Study for Pegtibatinase in 2026.
• The COMPOSE primary manuscript, highlighting positive results from the Phase 1/2 COMPOSE Study, has been accepted to Genetics in Medicine (GiM).

Negatives

• Selling, general, and administrative (SG&A) expenses increased to $72.8 million in Q1 2025, compared to $64.2 million in 2024.
• The company reported a net loss of $41.2 million for Q1 2025, although this is significantly improved from the $136.1 million loss in Q1 2024.

Risks

• The company faces risks related to the regulatory review and approval process for FILSPARI in FSGS.
• There is no guarantee that the FDA will approve FILSPARI for FSGS on the anticipated timeline, or at all.
• The company faces risks associated with the ongoing commercial launch of FILSPARI in IgAN, including market acceptance and competition.
• The company faces risks associated with global and macroeconomic conditions, including health epidemics and pandemics, which could disrupt clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The company anticipates continued growth for FILSPARI, driven by increased adoption and expansion into new indications like FSGS. They also expect to receive a milestone payment from CSL Vifor in Q2 2025 and are progressing with the development of Pegtibatinase.

Management Comments

• Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, stated that the company's strong start to the year reflects FILSPARI's leadership in IgAN.
• Eric Dube noted encouraging signs of a broader shift toward earlier treatment and lower proteinuria goals, which they believe will further amplify FILSPARI's growth potential.
• Eric Dube mentioned significant progress toward expanding FILSPARI into FSGS with the submission of their sNDA.

Industry Context

Travere Therapeutics is focused on rare kidney diseases, particularly IgAN and FSGS. The company's FILSPARI is positioned as a key therapy in these areas, competing with existing treatments and aiming to become the standard of care. The updated KDIGO guidelines recommending FILSPARI further solidify its position in the market.

Comparison to Industry Standards

• FILSPARI's 182% year-over-year growth in U.S. net product sales indicates strong market adoption compared to previous standards of care for IgAN.
• The submission of the sNDA for FSGS positions FILSPARI to potentially become the first and only approved medicine for this rare kidney disorder, setting a new benchmark in treatment.
• The Phase 3 DUPLEX study results showing earlier and more frequent proteinuria remission with FILSPARI compared to irbesartan demonstrate superior efficacy compared to existing treatments.

Stakeholder Impact

• Shareholders can expect potential growth in the company's value due to increased sales and potential new approvals.
• Patients with IgAN and FSGS may benefit from new treatment options and improved outcomes.
• Employees may experience job security and growth opportunities due to the company's positive performance.

Next Steps

• The company expects to receive notice regarding the acceptance and timeline for sNDA review from the FDA in May 2025.
• The company expects to receive a $17.5 million milestone payment from CSL Vifor in the second quarter of 2025.
• Renalys Pharma, Inc., expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan in the second half of 2025.
• The Company is on track to restart enrollment in the Phase 3 HARMONY Study in 2026.

Key Dates

Keywords

FILSPARI, sparsentan, IgAN, FSGS, Travere Therapeutics, Financial Results, Pegtibatinase, TVTX